Medicare to Offer $50/Month Weight Loss Drugs Starting July 2026: Key Facts for Beneficiaries

Medicare’s New Weight Loss Drug Pilot Program: What You Need to Know

Starting July 1, 2026, Medicare beneficiaries may access GLP-1 weight loss medications for a flat $50 per month copayment. This marks a significant shift for Medicare, which has historically excluded coverage for weight loss treatments. The covered drugs include:

• Wegovy (pill and injectable formulations)
• Zepbound (KwikPen formulation)
• Foundayo (pill)

Without insurance, these medications can cost between $149 and $699 per month, even with discounts. According to KFF polling, nearly half of GLP-1 users reported difficulty affording the drugs, with a quarter calling it “very difficult.”

The Medicare GLP-1 Bridge Program

The initiative, called the Medicare GLP-1 Bridge, is a short-term pilot program announced by the Centers for Medicare & Medicaid Services (CMS). It will operate from July 1, 2026, through December 31, 2027, serving as a temporary solution before a potential long-term program in 2028.

Eligibility Requirements

To participate, you must:

• Be enrolled in a Medicare Part D plan (prescription drug coverage).
• Meet weight and health criteria:
  • BMI of 27 or higher with a qualifying condition (e.g., heart disease, prediabetes).
  • BMI of 35 or higher (automatic qualification).

Approximately 40% of American adults have a BMI of 30 or higher, per the CDC.

How the Program Works

This benefit differs from standard Medicare coverage:

• Prior authorization required: Doctors submit prescriptions to a CMS contractor (Humana) via an existing Medicare drug program system.
• No Medicare provider enrollment needed for doctors to prescribe or request prior authorization.
• $50 copayment at the pharmacy upon approval.

Cost Savings and Accessibility

The program aims to reduce financial barriers. Without insurance, discounted prices for these drugs can still be high:

• Wegovy injectable: $199 (lower dosage, first two months) to $399 (higher dosage).
• Zepbound (KwikPen): Up to $699 per month.

The TrumpRx website, launched by the government, offers direct-to-consumer prescription drug discounts for uninsured patients, though this program provides a more structured alternative.

Key Considerations

The pilot program includes limitations:

• It is a temporary solution with no guarantee of continuation beyond 2027.
• Clinical guidelines and prior authorization are required.
• Future long-term coverage remains uncertain.

What’s Next for Medicare Beneficiaries?

Medicare beneficiaries should consult their Part D plan and healthcare providers to determine eligibility and next steps. The program’s success may influence future coverage decisions for weight loss medications.